Efbemalenograstim Alfa

CHEMBL4297950 Phase 4 Aprobado Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A long-acting G-CSF (granulocyte colony-stimulating factor) analog used to prevent neutropenia, a dangerous reduction in white blood cells, following chemotherapy. It stimulates the bone marrow to produce more infection-fighting white blood cells.

Áreas terapéuticas

Ovarian Cancer Breast Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A long-acting G-CSF (granulocyte colony-stimulating factor) analog used to prevent neutropenia, a dangerous reduction in white blood cells, following chemotherapy. It stimulates the bone marrow to produce more infection-fighting white blood cells.

Yes, Efbemalenograstim Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297950. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

¿Busca información accesible para el paciente?

Efbemalenograstim Alfa en PillFYI

Datos Rápidos

Sinónimos: 1

Enlaces externos

ChEMBL CHEMBL4297950

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.